PFG Investments LLC Acquires Shares of 23,650 Atossa Therapeutics, Inc. (NASDAQ:ATOS)

PFG Investments LLC bought a new stake in Atossa Therapeutics, Inc. (NASDAQ:ATOS) during the first quarter, HoldingsChannel.com reports. The institutional investor bought 23,650 shares of the company’s stock, valued at approximately $43,000.

Separately, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Atossa Therapeutics in the third quarter valued at $98,000. Institutional investors own 12.74% of the company’s stock.

Atossa Therapeutics Stock Performance

Shares of Atossa Therapeutics stock traded up $0.14 during trading hours on Friday, reaching $1.66. The company’s stock had a trading volume of 1,360,532 shares, compared to its average volume of 2,258,196. Atossa Therapeutics, Inc. has a one year low of $0.62 and a one year high of $2.31. The company’s 50 day simple moving average is $1.50 and its 200 day simple moving average is $1.05. The stock has a market cap of $208.00 million, a P/E ratio of -6.92 and a beta of 1.27.

Atossa Therapeutics (NASDAQ:ATOS) last released its quarterly earnings data on Monday, April 1st. The company reported ($0.06) earnings per share for the quarter. On average, sell-side analysts predict that Atossa Therapeutics, Inc. will post -0.28 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. HC Wainwright reissued a “buy” rating and issued a $4.00 target price on shares of Atossa Therapeutics in a research report on Tuesday, April 16th. Cantor Fitzgerald restated an “overweight” rating on shares of Atossa Therapeutics in a research note on Friday, January 12th. Finally, StockNews.com lowered Atossa Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, March 18th.

Insider Buying and Selling

In related news, Director Jonathan Finn acquired 25,000 shares of the stock in a transaction that occurred on Wednesday, April 10th. The stock was purchased at an average cost of $1.77 per share, for a total transaction of $44,250.00. Following the purchase, the director now directly owns 25,000 shares in the company, valued at $44,250. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 7.80% of the company’s stock.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.